Clinical trials referenced in this document:
Documents that mention this clinical trial
Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole
https://doi.org/10.1007/s40262-023-01228-4
Funding for this research was provided by:
HK inno.N Corp.
Article History
Accepted: 15 February 2023
First Online: 10 March 2023
Declarations
:
: This study was funded by HK inno.N Corp., Seoul, Republic of Korea.
: The authors declare no conflicts of interest in this work.
: The protocol and informed consent form of this study were reviewed and approved by the Ministry of Food and Drug Safety of Korea and by the Institutional Review Board at Seoul National University Hospital. This study was performed in accordance with the Korean Good Clinical Practice guidelines and the Declaration of Helsinki.
: Written consent was obtained from each subject prior to any study-related procedures.
: Not applicable.
: The individual de-identified participant data supporting published results are available with approval from the corresponding author on reasonable request, at any time after publication.
: Not applicable.
: YE and LS wrote the manuscript. YE and LS designed the research. YE, SCJ, I-JJ, and LS performed the research. YE and LS analyzed the data. All the authors reviewed and revised the paper. All the authors approved the final version of the manuscript.